

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
15 June 2023 (15.06.2023)



(10) International Publication Number  
**WO 2023/107697 A1**

(51) International Patent Classification:

A61K 31/17 (2006.01) A61P 7/00 (2006.01)  
A61K 31/5377 (2006.01) A61P 7/06 (2006.01)  
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2022/052411

(22) International Filing Date:

09 December 2022 (09.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/288,377 10 December 2021 (10.12.2021) US  
63/421,524 01 November 2022 (01.11.2022) US  
63/429,376 01 December 2022 (01.12.2022) US

(71) Applicant: GLOBAL BLOOD THERAPEUTICS, INC.

[US/US]; 181 Oyster Point Boulevard, South San Francisco,  
California 94080 (US).

(72) Inventors: BARTH, Aline; c/o Global Blood Therapeutics,

Inc., 181 Oyster Point Boulevard, South San Francisco,  
California 94080 (US). DUCHIN, Ken; c/o Global Blood  
Therapeutics, Inc., 181 Oyster Point Boulevard, South San  
Francisco, California 94080 (US). WASHINGTON, Carla  
B.; c/o Global Blood Therapeutics, Inc., 181 Oyster Point  
Boulevard, South San Francisco, California 94080 (US).  
LO, Arthur; c/o Global Blood Therapeutics, Inc., 181 Oyster  
Point Boulevard, South San Francisco, California 94080  
(US).

(74) Agent: ZIELINSKI, Bryan C. et al.; Pfizer Inc., 100 Route

206 North, Mail Stop: SOM-PPK4-LLA403, Peapack, NJ  
07977 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,  
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,  
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,  
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))

(54) Title: METHODS OF ADMINISTERING A MODULATOR OF HEMOGLOBIN



(57) Abstract: Provided herein are methods for treating sickle cell disease comprising administering Compound (I), a modulator of hemoglobin, according to certain dosing regimens.



WO 2023/107697 A1